Ferinject approved in China

Australian CSL Limited’s (ASX: CSL) recently-incorporated Swiss business CSL Vifor and its partner Fresenius Kabi today announced that China’s National Medical Products Administration (NMPA) has approved Ferinject (ferric carboxymaltose).

The drug is a preparation for intravenous iron therapy for the treatment of iron deficiency in adult patients for whom oral iron preparations are ineffective, cannot be used or for whom there is a clinical need to deliver iron rapidly. Ferinject has now received marketing authorization in 85 countries worldwide.

“We are thrilled about the marketing authorization of Ferinject, which is a milestone for Chinese patients living with iron deficiency or iron deficiency anemia,” said Hervé Gisserot, general manager of CSL Vifor, adding: “There is a high unmet need in China, which has the world’s largest iron deficiency population, and we are confident that Ferinject can make a meaningful difference in the treatment of these patients. At the same time, this is another important step in our goal to globalizing and maximizing the performance of our iron franchise as we look forward to bring this treatment to market as soon as possible.”